newsfilter
← Earnings
Earnings Releases·

RenovoRx — Third Quarter 2026 Earnings Summary

RenovoRx reported record third-quarter 2026 revenue of $1.07 million, representing a nearly 300% year-over-year increase driven by the commercialization of its RenovoCath device. The company expanded its active commercial cancer center customer base to 26 sites and maintained its full-year 2026 revenue guidance between $3.75 million and $4.25 million. Clinical progress included full enrollment in the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer and the initiation of new investigator-initiated trials exploring the TAMP platform in sarcoma and neoadjuvant settings. As of September 30, 2026, the company held $10.4 million in cash and cash equivalents, with operations funded through the second half of 2027.

Company
RENOVORX INC
Sector
Healthcare
Industry
Biotechnology